VaricellaPhase 4NCT02173899
Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine
A Phase 4 study testing varicella-1, varicella-3 and varicella-5 in people with Varicella, run by Changchun Keygen Biological Products Co., Ltd. at 1 site in China.
Trial summary
The purpose of this study is to observe the occurrence of adverse events, seroconversion rate and geometric mean titres(GMTs) of 2 doses of live attenuated varicella vaccine. Read more about this study
- Who is it for?
- Ages 1 year to 7 yearsHealthy volunteers can take part
- Conditions the study is for
- Varicella
- What is being tested?
- varicella-1, varicella-3 and varicella-5
- Type of treatment
- Vaccines
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 716 participants
- Where
- 1 siteChina
- Study dates
- Jun 2014to Aug 2014
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 7 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Parent/legal acceptable representative is willing and able to understand the protocol requirements and provide informed consent
- Participant is aged ≥ 1 year to ≤ 7 years
- Participant without preventive inoculation of varicella vaccine and previous history of chickenpox and zoster
- Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures
- Body temperature ≤ 37.5℃
Who cannot join
- Known allergy to any constituent of the vaccine
- Known acute illness, severe chronic disease, acute exacerbation of chronic disease and fever
- Known or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth
- Reported the history of allergies, convulsions, epilepsy, mental illness and brain disease and clear serious systemic reaction
- Failed to the Expanded Programme on Immunization(EPI)
- Receipt of any vaccine in the 4 weeks preceding the trial vaccination
Show all 13Show fewer
- Plan to receive any vaccine in the 4 weeks following the trial vaccination
- Known bleeding disorder
- Receipt of whole blood, blood plasma or immunoglobulin in the 5 months preceding the trial vaccination
- Reported the history of acute illness had need systemic antibiotics or antiviral treatment of infections in the 7 days preceding the trial vaccination
- An acute illness with or without fever (temperature ≥ 38.0℃) in the 3 days preceding enrollment in the trial
- Participation in any other interventional clinical trial
- Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the vaccine
Trial locations and contacts
1 site in 1 country.
China1 site
Shenzhen Luohu District Center for Disease Control and Prevention
Shenzhen, Guangdong
About this study
Official title: A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine
The purpose of this study is to observe the occurrence of adverse events, seroconversion rate and geometric mean titres(GMTs) of 2 doses of live attenuated varicella vaccine.
- Conditions
- Varicella
- Being tested
- varicella-1, varicella-3, varicella-5
- Medical subject headings
- Chickenpox
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
varicella-1Biological
Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
varicella-3Biological
Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
varicella-5Biological
Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
| Study group | Role | What they receive |
|---|---|---|
| varicella-1 | Experimental | The second varicella vaccine and 1 year of the interval time between 2 doses Receives: Biological: varicella-1 |
| varicella-3 | Experimental | The second varicella vaccine and 3 years of the interval time between 2 doses Receives: Biological: varicella-3 |
| varicella-5 | Experimental | The second varicella vaccine and 5 years of the interval time between 2 doses Receives: Biological: varicella-5 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Seroconversion rate and GMTs for live attenuated varicella vaccine
Measured: 35-42 days after the second dose
Secondary outcomes (1)
Occurrence of adverse events
Measured: within 30 days after the second dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2014 (estimated)
- Study startJun 2014
- Primary completionAug 2014
- Study completionAug 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for VaricellaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 716 participants (actual)
Sponsor and investigators
- Lead sponsor
- Changchun Keygen Biological Products Co., Ltd.
- Sponsor type
- University, hospital or other
- Collaborators
- Guangdong Provincial Institute of Biological Products And Materia Medica
- Responsible party
- Sponsor
- Investigators
- Huizhen Zheng, Master, Principal investigator, Guangdong Center for Disease Prevention and Control
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02173899
- Sponsor's protocol ID
- NCT02079605
- Status last verified
- Aug 2014
- First submitted
- 24 Jun 2014
- Last updated
- 1 Sep 2014
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine
- ClinicalTrials.gov ID
- NCT02173899
- Acronym / sponsor ID
- NCT02079605
- Conditions
- Varicella
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 716 participants (actual)
- Lead sponsor
- Changchun Keygen Biological Products Co., Ltd.University, hospital or other
- Collaborators
- Guangdong Provincial Institute of Biological Products And Materia Medica
- Study start
- Jun 2014
- Primary completion
- Aug 2014 (actual)
- Study completion
- Aug 2014 (actual)
- First posted
- 25 Jun 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to observe the occurrence of adverse events, seroconversion rate and geometric mean titres(GMTs) of 2 doses of live attenuated varicella vaccine.
Study design
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| varicella-1 | Experimental | Biological: varicella-1The second varicella vaccine and 1 year of the interval time between 2 doses |
| varicella-3 | Experimental | Biological: varicella-3The second varicella vaccine and 3 years of the interval time between 2 doses |
| varicella-5 | Experimental | Biological: varicella-5The second varicella vaccine and 5 years of the interval time between 2 doses |
Who may qualify
- Ages
- 1 year to 7 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- Parent/legal acceptable representative is willing and able to understand the protocol requirements and provide informed consent
- Participant is aged ≥ 1 year to ≤ 7 years
- Participant without preventive inoculation of varicella vaccine and previous history of chickenpox and zoster
- Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures
- Body temperature ≤ 37.5℃
Key exclusion criteria (13 listed)
- Known allergy to any constituent of the vaccine
- Known acute illness, severe chronic disease, acute exacerbation of chronic disease and fever
- Known or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth
- Reported the history of allergies, convulsions, epilepsy, mental illness and brain disease and clear serious systemic reaction
- Failed to the Expanded Programme on Immunization(EPI)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| varicella-1Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day | Biological | varicella-1 |
| varicella-3Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day | Biological | varicella-3 |
| varicella-5Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day | Biological | varicella-5 |
Primary outcome
Seroconversion rate and GMTs for live attenuated varicella vaccine
Time frame: 35-42 days after the second dose
1 secondary outcome
Occurrence of adverse events
Time frame: within 30 days after the second dose
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2014.
Related trials for Varicella
RecruitingPhase 1/2
Clinical Trial of Recombinant Herpes Zoster Vaccine (ZFA01 Adjuvant, CHO Cells)
Herpes Zoster
Active, not recruitingPhase 2
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
Herpes Zoster (HZ), Infectious Diseases
RecruitingPhase 1/2
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
Herpes Zoster
RecruitingPhase 4
Safety of the Herpes Zoster Subunit Vaccine in Lupus
Systemic Lupus Erythematosus
Active, not recruitingPhase 1/2
Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older
Herpes Zoster, Herpes Zoster Vaccine
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Huizhen Zheng, Master principal investigator
Guangdong Center for Disease Prevention and Control
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing varicella-1, varicella-3 and varicella-5 in people with Varicella, run by Changchun Keygen Biological Products Co., Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Sep 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Seroconversion rate and GMTs for live attenuated varicella vaccine (time frame: 35-42 days after the second dose). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2014.